Literature DB >> 18971541

A major haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study.

Tuomo Rankinen1, Timothy Church, Treva Rice, Nathan Markward, Steven N Blair, Claude Bouchard.   

Abstract

The goals of our study were to evaluate the haplotype pattern at the Rho-associated kinase 2 (ROCK2) locus and prospectively test the association between the ROCK2 haplotype-tagging single-nucleotide polymorphisms (tagSNPs) with hypertension for verified incident hypertensive patients (n=607) and healthy, normotensive controls (n=586) in a HYPGENE study. Rho-associated kinases (ROCKs) play a central role in signaling pathways that are involved in vascular smooth muscle contraction and endothelial nitric oxide availability. Using a set of stringent criteria (minor allele frequency>or=0.05, pairwise r2>or=0.95), we identified 18 tagSNPs from the 109 SNPs available in the HapMap Caucasian data set. TagSNPs were genotyped using the Illumina BeadStation platform. The 18 tagSNPs consisted of two linkage disequilibrium (LD) blocks. A haplotype defined by four SNPs (rs965665, rs10178332, rs6755196, rs10929732) in LD block 2 was recessively associated with a lower risk of hypertension (p=0.003). Homozygotes for the minor alleles had an 85% lower risk of hypertension than carriers of the common allele. The associations were independent of baseline age, cardiorespiratory fitness, body mass index, sex, and follow-up time. The LD block 2 spans about 137 kb of genomic DNA at the 5'-end of the ROCK2 locus and covers exons encoding the kinase domain of the protein. Our data strongly suggest that a major haplotype block at the ROCK2 locus is recessively associated with a lower risk of hypertension. Identification of functional mutation(s) could thus help in the development of ROCK2-specific treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971541      PMCID: PMC2596921          DOI: 10.1291/hypres.31.1651

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  23 in total

1.  GOLD--graphical overview of linkage disequilibrium.

Authors:  G R Abecasis; W O Cookson
Journal:  Bioinformatics       Date:  2000-02       Impact factor: 6.937

2.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

3.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

4.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.

Authors:  Dale R Nyholt
Journal:  Am J Hum Genet       Date:  2004-03-02       Impact factor: 11.025

5.  Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.

Authors:  A Masumoto; Y Hirooka; H Shimokawa; K Hironaga; S Setoguchi; A Takeshita
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

6.  Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation.

Authors:  Y Kureishi; S Kobayashi; M Amano; K Kimura; H Kanaide; T Nakano; K Kaibuchi; M Ito
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

7.  Human blood pressure determination by sphygmomanometry.

Authors:  D Perloff; C Grim; J Flack; E D Frohlich; M Hill; M McDonald; B Z Morgenstern
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

8.  The molecular basis of dominance.

Authors:  H Kacser; J A Burns
Journal:  Genetics       Date:  1981 Mar-Apr       Impact factor: 4.562

9.  Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)

Authors:  K Kimura; M Ito; M Amano; K Chihara; Y Fukata; M Nakafuku; B Yamamori; J Feng; T Nakano; K Okawa; A Iwamatsu; K Kaibuchi
Journal:  Science       Date:  1996-07-12       Impact factor: 47.728

10.  Cardiorespiratory fitness, BMI, and risk of hypertension: the HYPGENE study.

Authors:  Tuomo Rankinen; Timothy S Church; Treva Rice; Claude Bouchard; Steven N Blair
Journal:  Med Sci Sports Exerc       Date:  2007-10       Impact factor: 5.411

View more
  16 in total

Review 1.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

Review 2.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 3.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Authors:  C Hahmann; T Schroeter
Journal:  Cell Mol Life Sci       Date:  2009-11-12       Impact factor: 9.261

Review 4.  Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Small GTPases       Date:  2014-10-31

Review 5.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

Review 6.  Potential benefits of rho-kinase inhibition in arterial hypertension.

Authors:  Olaf Grisk
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

Review 7.  Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

Authors:  Ming Dong; Bryan P Yan; James K Liao; Yat-Yin Lam; Gabriel W K Yip; Cheuk-Man Yu
Journal:  Drug Discov Today       Date:  2010-06-25       Impact factor: 7.851

8.  Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression.

Authors:  Yi-Chu Liao; Ping-Yen Liu; Hsiu-Fen Lin; Wen-Yi Lin; James K Liao; Suh-Hang H Juo
Journal:  J Mol Cell Cardiol       Date:  2014-12-03       Impact factor: 5.000

9.  Genetic variants in Arhgef11 are associated with kidney injury in the Dahl salt-sensitive rat.

Authors:  Jan M Williams; Ashley C Johnson; Cary Stelloh; Albert W Dreisbach; Nora Franceschini; Kevin R Regner; Raymond R Townsend; Richard J Roman; Michael R Garrett
Journal:  Hypertension       Date:  2012-09-17       Impact factor: 10.190

Review 10.  Druggable targets in the Rho pathway and their promise for therapeutic control of blood pressure.

Authors:  Rachel A Dee; Kevin D Mangum; Xue Bai; Christopher P Mack; Joan M Taylor
Journal:  Pharmacol Ther       Date:  2018-09-04       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.